Evidence map›Paper›PMID 22509348›Full record

ArticlePloS one2012

Chemerin and adiponectin contribute reciprocally to metabolic syndrome.

Sang Hui Chu, Mi Kyung Lee, Ki Yong Ahn, Jee-Aee Im, Min Soo Park, Duk-Chul Lee, Justin Y Jeon, Ji Won Lee

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021.International journal of molecular sciences · 2022
    Review
  16. Review
  17. Observational
  18. Novel Targets for Hypertension Drug Discovery.Current hypertension reports · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Sang Hui ChuDepartment of Clinical Nursing Science, Yonsei University College of Nursing, Nursing Policy and Research Institute, Biobehavioral Research Center, Seoul, Korea.
Mi Kyung Lee
Ki Yong Ahn
Jee-Aee Im
Min Soo Park
Duk-Chul Lee
Justin Y Jeon
Ji Won Lee
Yonsei University · KRSeverance Hospital · KRToto (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity and metabolic syndrome (MetS) are considered chronic inflammatory states. Chemerin, a novel adipokine, may play an important role in linking MetS and inflammation. We investigated the association of chemerin with inflammatory markers and with characteristics of MetS in apparently healthy overweight and obese adults. We studied 92 adults; 59 men and 33 women whose average body mass index (BMI) was 28.15 ± 5.08 kg/m(2). Anthropometric parameters, insulin resistance indices, lipid profiles, and inflammatory markers including high sensitivity C-reactive protein (hsCRP), pentraxin 3 (PTX3), adiponectin, and chemerin were measured. Controlling for age, gender, and BMI, serum chemerin level was positively correlated with body fat and serum triglyceride, and negatively correlated with adiponectin and high density lipoprotein cholesterol (HDL- C), and was not correlated with altered hsCRP or PTX3 levels. Among the low, moderate and high chemerin groups, high chemerin individuals are more likely to have lower HDL-C. Conversely, individuals in the low adiponectin group are more likely to have lower HDL-C and show more MetS phenotypic traits than moderate and high adiponectin subjects. To determine the relationships of chemerin and adiponectin to MetS and its components, participants were stratified into four groups based on their chemerin and adiponectin levels (high chemerin/high adiponectin, high chemerin/low adiponectin, low chemerin/high adiponectin, or low chemerin/low adiponectin). Participants who were in the high chemerin/low adiponectin group more likely to have dyslipidemia and MetS (OR: 5.79, 95% CI:1.00-33.70) compared to the other three group. Our findings suggest that chemerin and adiponectin may reciprocally participate in the development of MetS.

Indexed as

AdiponectinAdipose TissueAdultBody Mass IndexChemokinesCholesterol, HDLC-Reactive ProteinFemaleHumansIntercellular Signaling Peptides and ProteinsMaleMetabolic SyndromeObesityPentraxinsSerum Amyloid P-ComponentTriglyceridesAdiponectinChemokinesCholesterol, HDLC-Reactive ProteinIntercellular Signaling Peptides and ProteinsPentraxinsRARRES2 protein, humanSerum Amyloid P-ComponentTriglycerides

Identifiers

PMID22509348
PMCPMC3324504
OpenAlexW2000790912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.